Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
The herpes simplex virus type 1 (HSV-1) glycoprotein B (gB-1) gene, deleted of 639 nucleotides that encode the transmembrane anchor sequence and reconstructed with the extramembrane and intracytoplasmic domains, was cloned under control of the Rous sarcoma virus long terminal repeat in the episomal replicating vector pRP-RSV, which contains the origin of replication and early region of the human papovavirus BK as well as a cDNA for a mutant mouse dihydrofolate reductase that is resistant to methotrexate. gB-1 (0.15 to 0.25 pg per cell per 24 h) was constitutively secreted into the culture medium of pRP-RSV-gBs-transformed human 293 cells. Treatment of transformed cells with methotrexate at high concentrations (0.6 to 6 microM) increased gB-1 production 10- to 100-fold, because of an amplification of the episomal recombinant. Mice immunized with secreted gB-1 produced HSV-1- and HSV-2-neutralizing antibodies and were protected against HSV-1 lethal, latent, and recurrent infections. Constitutive expression of secreted gB-1 in human cells may establish a system to develop diagnostic material and a subunit vaccine for HSV infections.
Manservigi
R
R
Institute of Microbiology, School of Medicine, University of Ferrara, Italy.
Grossi
M P
MP
Gualandri
R
R
Balboni
P G
PG
Marchini
A
A
Rotola
A
A
Rimessi
P
P
Di Luca
D
D
Cassai
E
E
Barbanti-Brodano
G
G
D000818:Animals; D001739:BK Virus / Q000235:genetics*; D015139:Blotting, Southern; D005260:Female; D015870:Gene Expression; D005814:Genes, Viral; D005822:Genetic Vectors; D006561:Herpes Simplex / Q000276:immunology* / Q000517:prevention & control; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009693:Nucleic Acid Hybridization; D010957:Plasmids; D011120:Polyomavirus / Q000235:genetics*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D018139:Simplexvirus / Q000235:genetics / Q000472:pathogenicity*; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D015678:Viral Structural Proteins / Q000235:genetics
D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; D015678:Viral Structural Proteins; C040495:glycoprotein B, Simplexvirus